ARTICLE | Clinical News
EV06: Completed Phase I/II enrollment
February 1, 2016 8:00 AM UTC
Encore completed enrollment of 75 patients ages 45-55 in a double-blind, placebo-controlled, U.S. Phase I/II trial evaluating topical EV06 for 90 days. ...
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
Encore completed enrollment of 75 patients ages 45-55 in a double-blind, placebo-controlled, U.S. Phase I/II trial evaluating topical EV06 for 90 days. ...